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Background: To determine the prevalence of uncontrolled LDL-C in patients with high cardiovascular disease
(CVD) risks across Canada and to examine its related factors.
Methods: Non-pregnant adults >20 years-old, who had a lipid test completed between January 1, 2009 and
December 31, 2011 and were included in the Canadian Primary Care Surveillance Network (CPCSSN) database were
studied. The Framingham-Risk-Score was calculated to determine the risk levels. A serum LDL-C level of >2.0 mmol/L
was considered as being poorly controlled. Patients with a previous record of a cerebrovascular accident, peripheral
artery disease, or an ischemic heart disease were regarded as those under secondary prevention. Logistic regression
modeling was performed to examine the factors associated with the LDL-C control.
Results: A total of 6,405 high-risk patients were included in the study and, of this population, 68 % had a suboptimal
LDL-C, which was significantly associated with the female gender (OR: 3.26; 95 % CI: 2.63–4.05, p < 0.0001) and no
medication therapy (OR: 6.31, 95 % CI: 5.21–7.65, p < 0.0001). Those with comorbidities of diabetes, hypertension, obesity,
and smokers had a better LDL-C control. Rural residents (OR: 0.64, 95 % CI: 0.52–0.78, p < 0.0001), and those under
secondary prevention (OR: 0.42; 95 % CI: 0.35–0.51, p < 0.0001), were also more likely to have a better LDL-C control.
Conclusion: A high proportion of high-cardiac risk patients in Canadian primary care settings have suboptimal LDL-C
control. A lack of medication therapy appears to be the major contributing factor to this situation.
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Cardiovascular diseases (CVD) are the leading cause of
death worldwide with more than 17.3 million deaths in
2008 according to a WHO report [1]. In Canada, CVD
is the main cause of death at 32 % and, after musculo-
skeletal diseases, has the highest economic burden of* Correspondence: shabnam.asghari@med.mun.ca
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creativecommons.org/publicdomain/zero/1.0/disease [2]. Hyperlipidemia, defined as abnormal blood
lipid levels including elevated total cholesterol, low-
density lipoprotein cholesterol (LDL-C), triglycerides
and decreased high-density lipoprotein cholesterol, is
well established as a major risk factor to CVD [3]. Simi-
lar to many other countries, the management of dyslip-
idemia, in order to reduce the CVD risk in a clinical
setting in Canada, is conducted following the instruc-
tions by the available guidelines, including those by the
Canadian Cardiovascular Society [4]. These guidelines
are modeled after the Framingham Risk Assessment and
target specific lipid goals based on the cardiovascularss article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Fig. 1 The flowchart of the study
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are treated more aggressively than those with a lower
risk. Thus, patients with a 10-year cardiovascular risk of
>20 % will have an LDL-C goal of ≤2 mmol/L, while pa-
tients with a 10-year cardiovascular risk of <5 % may or
may not be treated depending on their initial LDL-C
levels. The LDL-C reduction is primarily administered
by medication therapy, although diet and physical activ-
ity have also been suggested to be effective [5]. Statins
are the most commonly used medications for lowering
LDL-C levels. Every 1.0 mmol/L reduction in LDL-C by
statins has been reported to be associated with a ~23 %
relative risk reduction in major vascular events over five
years of treatment and follow-up [6]. A 2.0 mmol/L ab-
solute reduction, or a 50 % relative reduction in LDL-C,
provides optimal benefits in CVD risk management;
thus, those with a higher CVD risk are more likely to
benefit from the management of dyslipidemia [4]. Lipid
level targets, however, are sometimes challenging to
achieve. While various reports suggest that LDL-C levels
are not lowered to target a significant portion of the
high-risk populations [6–8], there is no recent report
available on the status of LDL-C control among Canadian
patients at risk. Canadian guidelines for the diagnosis and
treatment of dyslipidemia [4] recommend an LDL-C
target goal of ≤2.0 mmol/L for individuals with a high 10-
year risk of a cardiovascular event. In the present study, we
determine the prevalence of suboptimal LDL-C (LDL-C >
2 mmol/L) in high-risk individuals in a primary care setting
in Canada. As well, we examine the factors associated with
the rates of LDL-C control.
Results
Among the 22,101 individuals who met the inclusion
criteria (Fig. 1), 6,405 (29 %) were classified as high risk,
and were included in the analysis (aged 71.9 ± 10.3, 23 %
female, 24 % rural residence). Almost half of the popula-
tion (46 %) was classified as non-medication users,
whereas 12 % and 41.5 % were previous and current
users, respectively. The prevalence of those with uncon-
trolled LDL-C was 68 % and 29 % were determined to
be in need of secondary prevention (Fig. 1).
As seen in Table 1, the prevalence of uncontrolled
LDL-C gradually decreases with age. High-risk females
have a higher rate of uncontrolled LDL-C (77 %) com-
pared to high-risk males with 66 %. Whereas 89 % of
non-medication users have sub-optimal LDL-C, the
rates are much lower to about 50 % only among previ-
ous and current medication users. The rates are ap-
proximately 30 % higher among those under primary
prevention than those individuals under secondary
prevention. Diabetic high-risk patients, however, had a
30 % lower rate of uncontrolled LDL compared to
non-diabetics (Table 1).Table 2 represents the charachteristics of the study
population among those with uncontrolled and con-
trolled levels of LDL-C. Table 3 shows the results of the
logistic regression model in the high-risk population,
adjusting for gender, age, place of residence, comorbidi-
ties, and type of prevention. As observed, women are
more likely to have an LDL-C above 2.0 mmol/L than
men (OR: 3.26; 95 % CI: 2.63–4.05, p < 0.0001), and
aging is significantly associated with the lower odds of hav-
ing an uncontrolled LDL-C (OR: 0.95, 95 % CI: 0.94–0.96,
p < 0.0001). Comorbidities were associated with a lower rate
of suboptimal LDL-C (obesity [OR: 0.62, 95 % CI: 0.46–
0.84, p = 0.002], current smokers [OR: 0.44, 95 % CI: 0.33–
0.59, p < 0.0001], diabetes [OR: 0.13, 95 % CI: 0.11–0.16,
p < 0.0001], and hypertension [OR: 0.72, 95 % CI: 0.61–
0.86, p < 0.0001]). Individuals who were not receiving any
lipid-lowering medication had a 6.31 (95 % CI: 5.21–7.65)
fold increased odds of having an LDL-C above 2 mmol/L
compared to current medication users (p < 0.0001). Rural
residents had a better LDL-C control (OR: 0.64, 95 % CI:
0.52–0.78, p < 0.0001) compared to urban dwellers. Pa-
tients who were being treated for the purpose of sec-
ondary prevention were better controlled in terms of
LDL-C (OR: 0.42; 95 % CI: 0.35–0.51, p < 0.0001) than
patients who were being treated for the purpose of pri-
mary prevention.
Table 1 Prevalence of uncontrolled LDL among high-risk patients
in Canadian EMR primary care settings by category of risk factors
Risk factors High-risk patients
Total (n = 6405) Uncontrolled LDL (68.6 %)
Gender
Male 4931 66.0 %
Female 1474 77.3 %
Age
< 40 2 100.0 %
40–50 72 85.7 %
50–60 599 81.2 %
60–70 1726 72.5 %
70–80 2185 66.3 %
> 80 1821 63.0 %
Smoking status
Current smokers 1396 73.5 %
Past smokers 2850 64.1 %
Non-smokers 2159 71.4 %
Diabetes
Diabetics 2715 51.6 %
Non-diabetics 3690 81.0 %
Hypertension
Hypertensive 3911 66.9 %
Non-hypertensive 2494 71.2 %
Obesity
Normal/underweight 1218 70.5 %
Overweight 2754 70.3 %
Obese 2433 61.1 %
Lipid-lowering medication use
Non-users 2958 89.5 %
Previous users 789 50.4 %
Current users 2658 50.6 %
Place of residence
Rural 4754 70.5 %
Urban 1501 67.8 %
Type of prevention
Primary 4508 77.3 %
Secondary 1897 47.9 %
Table 2 CVD associated factors among high-risk patients with
and without controlled levels of LDL-C in Canadian EMR primary
care settings
Risk factors Controlled LDL Uncontrolled LDL P-value
Age (Mean ± SD) 73.80 ± 9.57 71.27 ± 10.4 <0.0001
Gender (female) 17.5 % 26.5 % <0.0001
Body mass index
(Mean ± SD)
29.93 ± 5.84 28.85 ± 5.39 <0.0001
Diabetes 65 % 32 % <0.0001
Hypertension 64 % 59 % <0.0001
Smoking
Non-smokers 30.8 % 35.2 % <0.0001
Past smokers 50.9 % 41.6 %
Current smokers 18.1 % 23.1 %
Lipid-lowering medication use
Non-user 15.5 % 60.4 % <0.0001
Previous user 19.3 % 8.9 %
Current user 65.1 % 30.6 %
Residence (rural) 22.3 % 25.1 % 0.055
Prevention (secondary) 49.00 % 20.60 % <0.0001
Table 3 Multivariate logistic regression model for uncontrolled LDL
among high risk patients in Canadian EMR primary care settingsa
Risk factors (reference group) Odds ratio (95%CI) P-value
Gender (males) 3.26 (2.63–4.05) <0.0001
Age 0.95 (0.94–0.96) <0.0001
Obesity (BMI ≤25)
Overweight 1.05 (0.77–1.42) 0.775
Obese 0.62 (0.46–0.84) 0.002
Smoking status (nonsmokers)
Past smokers 0.85 (0.71–1.01) 0.062
Current smokers 0.44 (0.33–0.59) <0.0001
Diabetes 0.13 (0.11–0.16) <0.0001
Hypertension 0.72 (0.61–0.86) <0.0001
Lipid-lowering medication (current users)
Previous users 1.28 (1.02–1.61) 0.035
Non-users 6.31 (5.21–7.65) <0.0001
Place of residence (urban) 0.64 (0.52–0.78) <0.0001
Type of prevention (primary) 0.42 (0.35–0.51) <0.0001
a Patients with diabetes and hypertension were compared to those without
diabetes or hypertension, respectively
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Our study is the first of its kind to assess the status of
LDL-C control in a targeted population for CVD pri-
mary and secondary prevention in a primary care setting
across Canada. We used a cross-sectional study design
using the electronic medical records of the Canadian
population under primary care that is at a high risk for
CVD. The information for risk calculation was only
available for less than a quarter of the subjects who hada record of completing a lipid test; this is mainly due to
the missing information on smoking (~70 %), suggesting
that FRS is not measured for a large proportion of pa-
tients in primary care despite the recommendations by
the guidelines. It also indicates that the smoking status,
a well-known risk factor of CVD, is not regularly tracked
and recorded by family physicians. This raises the ques-
tion as to what extent the FRS is being practiced and
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since many practitioners might use other criteria as an
indication of LDL-C lowering treatment. Nevertheless,
according to our findings, approximately three-quarters
of the high-risk population have poorly controlled LDL-
C. The status of control is better among men, the eld-
erly, rural residents, those under secondary prevention
management, those taking lipid modifying agents, and
those with comorbidities. In our study, lipid modifying
agents have the greatest effect on the status of LDL-C
control. Non-medication users have 6.3 fold increased
odds of having poorly controlled LDL-C compared to
current users. Previous medication users were not sig-
nificantly different compared with non-users, which sug-
gests that the effect of lipid lowering medications does
not endure three months from cessation. Approximately
90 % of the lipid lowering medication users were on sta-
tins; similar results were identified where we limited the
study to statin users. Therefore, it could be hypothesized
that a lack of medication therapy may be a major contribu-
tor to a low rate of LDL-C control in Canada, which may
possibly be related to a lack of updated knowledge among
physicians or the unwillingness of patients to participate in
medication therapy. Since half of the current medication
users still have suboptimal levels of LDL-C, other factors,
such as a lack of physical activity and appropriate dieting
among the patients, as well as the satisfaction of physicians
with LDL-C levels reaching close to the cut-off point, may
also be considered. Moreover, of special importance are
the status of nutrition and the use of nutraceutical in treat-
ing dyslipidemia, given that several studies report that
these agents, in addition to statin therapy, need to be con-
sidered in treating dyslipidemia [7]. Since we did not have
access to this information, our multivariate model cannot
predict the effect of these factors.
Although the number of similar studies performed on
LDL-C control worldwide is limited and, to our know-
ledge, no such report is available from Canada, the find-
ings of this study are comparable to those few studies
conducted elsewhere. In a Chinese study, only 37 % of pa-
tients with Coronary Heart Disease had a desirable LDL-C
level [8]. This figure was lower among very high-risk pa-
tients and differed among the two genders and various age
groups. In a Brazilian study, only 30 % of the patients ob-
tained the advisable LDL-C levels and the rates were sig-
nificantly lower among those with poor income [9]. A
recent study of 17.5 million statin treated high-risk adults
in the United States [10] found that ~30 % of the statin-
treated patients had not reached the recommended LDL-C
levels of 100 mg/dl (2.5 mmol/L), and ~75 % had an
LDL-C >70 mg/dl (1.8 mmol/L) deemed optional accord-
ing to the American guidelines [11] at the time of the
study. These figures would possibly increase if the study
had taken into consideration the untreated populations.The main recommendation by the Canadian guide-
lines for high-risk patients is to reduce the LDL-C
to ≤2.0 mmol/L. Alternatively, an ≥50 % reduction
from the baseline LDL-C, in addition to an apoB target
level of less than 0.8 g/L, can be implemented. It might
be possible that some of the health-care providers fol-
low the alternative recommendations based on which the
LDL-C levels do not have to be lowered to 2.0 mmol/L.
Otherwise, they might have not found the presented evi-
dence by the guidelines compelling and made an informed
valued decision not to initiate pharmacologic treatment.
These inconsistencies may account for a portion of those
with uncontrolled LDL-C, a subject matter that is not pos-
sible to assess merely from electronic medical records,
since we did not have access to the baseline levels of lipids
at the time the therapy was initiated for the patients.
This study is limited by several factors; i.e., the high risk
population was defined according the Canadian Cardio-
vascular Guidelines at the time of the study (2009) [4]. Re-
cent cardiovascular guidelines still consider FRS ≥20 % as
a high risk of CVD; however, other disease conditions,
e.g., patients with chronic kidney disease have been added
to the high-risk groups and recommended for cardiovas-
cular risk management. The patients in our study are not
treated and evaluated according to the new guidelines and
thus their status of the newly added high-risk medical con-
ditions is not known.
Among the 128,825 individuals who had lipid testing
during the study period, 22,101 (<20 %) individuals had
a measure of cardiovascular risk factors within six
months of the lipid tests. In order to avoid the possibility
of bias due to the unavailable information, we compared
the LDL-C levels of those with and without risk classifi-
cation data. We observed a minimal difference between
the two groups suggesting a low possibility of selection
bias (uncontrolled LDL-C: 80 vs. 83 %, LDL-C levels:
2.91 vs. 2.87 mmol/dl, respectively).
The cross-sectional nature of the study did not accur-
ately permit the interpretation of the causal and tem-
poral relationships across the variables. As such, the
relationship between LDL-C control and its associated
factors, including CVD, diabetes and hypertension,
should be interpreted with caution in terms of the thera-
peutic regime suggested by the CVD prevention guide-
lines for patients with those conditions [4]. Since a
similar pattern is observed for aging, obesity and smok-
ing, the latter explanation seems more likely as all of the
patients in our study were high risk and most likely
under more stringent therapeutic measures. These fac-
tors are indicators of higher Framingham-Risk-Scores
and it is more likely to draw the attention of the practi-
tioners to such treatments. As well, it was not possible
to represent the variability of lipid and risk levels over
time, given that they change constantly. We did not have
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medication users were on adequate dosage; however, the
study findings show that lipid-lowering medication users
were more likely to attain the lipid goals compared to
non-users. There was no information available from the
family histories of the patients on the comorbidities,
such as Type II Diabetes, which is known to increase the
risk of CVDs in the non-diabetes population [12, 13]. Fi-
nally, the prevention class categorization may not be
ideal, given that the database included information from
the year 2006 onward. In that regard, the patients would
still be classified into primary prevention, despite the
possibility of a disease condition CVED or IHD occur-
rence before 2006, even though previous studies show
that physicians keep updated EMR profiles of those
patients at risk of cardiovascular diseases [14].
Conclusion
A large portion of high-risk patients in Canada have sub-
optimal LDL-C control. A lack of medication therapy
seems to be the most potential contributing factor to this
condition, which could result from alternative recommen-
dations or informed decisions by the health-care providers.
Our data suggests that there is significant opportunity for
improvement. Further studies may also be needed to eluci-
date other potential causes of uncontrolled LDL-C in
Canada, specifically variations in medical practice and pa-
tients’ adherence and tolerance. In addition, providers in
the health-care system need to identify the barriers to
medication adherence and implement new methods to im-
prove medication adherence in high-risk patients.
Methods
Study design
This is a cross-sectional study using a secondary analysis
of the data from the Canadian Primary Care Sentinel
Surveillance Network (CPCSSN) database.
Data source
CPCSSN is Canada’s first library of digital information
based on point-of-care data from primary-care practices.
Data from these EMRs is extracted quarterly and
uploaded in a de-identified format to both regional and
central (pan-Canadian) databases. The database contains
a comprehensive record of all diagnoses, health condi-
tions, risk factors, laboratory tests, medication use, as
well as other services provided by family physicians in
Canada. It is increasingly used for chronic disease sur-
veillance in primary care and also as a tool for conduct-
ing primary-care research [15]. At the time of this
study, the CPCSSN database included data from close
to 600 primary-care clinicians in rural and urban set-
tings across ten Canadian provinces with data on
844,592 individuals [16].Study population
The study population included adults at high risk of
CVD according to Canadian guidelines at the time of
the study [4]. According to these guidelines, the patients
with a 10-year risk ≥20 % of developing CVD were con-
sidered as high risks and were included in the study.
To identify the high-risk patients, all non-pregnant
adults aged 20 years and older who had a lipid profile in
their record between January 1, 2009 and December 31,
2011 were identified from the CPCSSN database. The
10-year risk score of CVD was calculated using the risk
factors measured within six months of the lipid tests ac-
cording to the Framingham Risk Assessment (FRS) chart
for a 10-year risk of a total CVD event [4].
Variables required for CVD risk estimation, including
comorbidities, level of blood lipids, level of systolic
blood pressure, smoking status and medical history were
extracted from the CPCSSN database. The most recent
information regarding the lipid levels and the variables
required for CVD risk estimation from every patient,
was used in the event that the patient was visited mul-
tiple times during the study period.
Study variables
LDL-C control is the primary outcome variable in this
study. High-risk patients with a serum LDL-C level
≥2.0 mmol/L were considered as being poorly con-
trolled, whereas those with lower LDL-C levels were
regarded as being well controlled.
Independent variables, including age at the time of the
lipid test, gender, place of residence, body mass index,
smoking status, medical history of diabetes, hypertension
and lipid lowering medication use were extracted from
the database. Diabetes and hypertension were defined
using CPCSSN algorithms for chronic conditions [17]
which have high sensitivity, specificity and positive pre-
dictive value to detect these conditions with all scores
being over 80–90 % [18, 19]. Obesity was defined as
BMI ≥30; whereas those with BMI lower than 30, but
higher than 25, were classified as overweight. The smok-
ing status was extracted from the most recent record by
the family physician at the time of the lipid test, and in-
dividuals were classified as non-smokers, past smokers,
and current smokers. Place of residence (rural/urban)
was determined using the first two characters of the pos-
tal code from each individual.
Lipid lowering medication (HMG-CoA reductase in-
hibitors, Fibrates, Bile Acid Sequestrants, Nicotinic Acid,
and other agents) usage was classified into three categories
as follows: 1) current user was defined as lipid-lowering
medication use at the time of the lab test (started before
the date of blood test and did not stop up to three months
before the time of the blood test); 2) previous user was de-
fined as the existence of any record of lipid-lowering
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test and a record of discontinuation of at least three
months before the date of the lab test; and 3) non-user
was defined as no record of medication use within two
years of the lab test. The type of lipid lowering medica-
tions was not specified in the analysis since more than
90 % of the medication users were on statins.
Patients with any record (diagnostic text, ICD code)
of previous Ischemic Heart Disease (IHD), Peripheral
Vascular Disease (PVD), or Cerebrovascular Disease
(CVD) were categorized as those under secondary pre-
vention. All other patients with no record of these con-
ditions in the same period were regarded as those in
need of primary prevention.
Statistical analysis
Characteristics of the study population, as well as the
mean and confidence intervals of the individual lipid
components, were summarized using descriptive statis-
tics. Classical tests of hypothesis, including the student’s
T-test and the chi-squared test, were conducted to test
for the association between variables. Logistic regression
modeling was used to examine the association between
LDL-C control status and possible influencing factors.
Variable age was treated continuously. A p-value of less
than 0.05 was considered statistically significant. All ana-
lyses were performed using STATA/SE 11.2 (Stata Corp.,
College Station, Texas, USA).
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